





When insulin has to work hard to keep the sugar at bay the upper airway collapses away

Danny J. Eckert¹ and Arie Oliven²

Affiliations: ¹Neuroscience Research Australia (NeuRA) and the School of Medical Sciences, University of New South Wales, Sydney, Australia. ²Dept of Medicine, Bnai-Zion Medical Center and the Technion, Haifa, Israel.

Correspondence: Danny J. Eckert, Neuroscience Research Australia (NeuRA), PO Box 1165, Randwick, Sydney, New South Wales, Australia, 2031. E-mail: d.eckert@neura.edu.au



@ERSpublications

Insulin resistance may increase upper airway collapsibility and directly contribute to sleep apnoea pathogenesis http://ow.ly/10BTf9

Obesity is a major risk factor for both obstructive sleep apnoea (OSA) and metabolic disease. As obesity rates continue to rise, so too does the prevalence of OSA and metabolic disorders. Indeed, recent community sample data from over 2000 adults aged 40–85 years in Switzerland indicate that up to 50% of men and almost a quarter of women have apnoea–hypopnoea indices (AHI) within the moderate to severe range (>15 events·h⁻¹ sleep) [1]. Insulin resistance, a strong predictor for the development of type 2 diabetes [2], is being recognised earlier with prevalence rates in children varying between 3 and 44% [3]. Thus, OSA and insulin resistance are major health issues.

Given the shared link with obesity, the connection between metabolic disruption and OSA is not new. Indeed, OSA has been implicated in the pathogenesis of metabolic dysfunction [4–6]. Furthermore, a "bidirectional" or "reciprocal" relationship, or the possibility that OSA is a manifestation of the metabolic syndrome, has been discussed in several publications [7–10]. However, while evidence continues to grow that sleep-disordered breathing and sleep disruption can worsen metabolic function including insulin resistance [11], there is currently limited direct evidence to support the concept that early biomarkers of metabolic dysfunction such as insulin resistance predispose to OSA [12, 13]. Thus, the chicken or the egg causality dilemma remains.

The new study by LLANOS et al. [14] in this issue of the European Respiratory Journal takes us one step closer to solving this dilemma. Specifically, the authors have provided elegant insight into this question by going to the source; evaluating the relationship between pre- diabetes (i.e. insulin resistance), and "pre-OSA" (i.e. individuals with vulnerable upper airways due to high mechanical load from morbid obesity but without frank OSA (AHI <10 events/h sleep)). This unique approach has allowed the investigators to study upper airway collapsibility during sleep, using the gold standard critical closing pressure or "Pcrit" technique, without the confounding effects of prior exposure to repetitive severe hypoxaemia and sleep fragmentation, both of which contribute to metabolic sequelae [5, 15]. Accordingly, consistent with insulin resistance preceding the decline in pharyngeal stability, the reported positive correlation between insulin resistance and upper airway collapsibility and the ~4 cmH₂O increase in Pcrit when the group was dichotomised according to high versus low insulin resistance cannot be explained by the presence of severe sleep-disordered breathing.

Received: March 22 2016 | Accepted: March 23 2016

Support statement: D.J. Eckert is supported by a National Health and Medical Research Council (NHRMC) of Australia. R.D. Wright Fellowship (1049814). Funding information for this article has been deposited with FundRef.

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Copyright ©ERS 2016

In addition to a causal role, these novel findings suggest that insulin resistance may also accelerate the development of OSA and its aggravation once manifested. Thus, the following question arises: what has the pancreas/insulin resistance got to do with upper airway collapsibility? As discussed below, there are several plausible mechanisms by which insulin resistance may increase pharyngeal collapsibility and possibly cause frank OSA, each of which will require careful future investigation (summarised in figure 1).

Pharyngeal stability is dependent on the interaction between anatomical or static properties of the upper airway and the dynamic function of the dilator muscles [16]. Static properties include: cross sectional area, pharyngeal length and structural composition. Dynamic properties include: neural drive, coordination and muscle efficiency. The anatomic features govern the static shape and size of the upper airway whereas the dynamic components mediate the ability of the pharyngeal dilators to compensate for mechanical loads to the upper airway (e.g. obesity chronically or transient repetitive narrowing and closure as occurs during sleep in OSA). The Llanos et al. study [14] used the "passive Pcrit" technique to focus on the effects of insulin resistance on the static properties. As highlighted by the authors, factors that crowd the upper airway directly such as preferential ectopic fat accumulation in the tongue or peripharyngeal tissues with insulin resistance will increase upper airway collapsibility. Indirectly, visceral fat accumulation which is closely linked to insulin resistance will lower lung volume during sleep and make the upper airway more prone to collapse via a loss of tracheal traction [17]. To determine if these regional changes in fat distribution are indeed the key mechanisms explaining the current findings, sophisticated imaging approaches of the key upper airway structures and lateral fat pads of the neck combined with respiratory physiology work is required [18–20].

Although not the focus of the present study, insulin resistance may also alter the dynamic properties of the upper airway. The pharyngeal dilator muscles receive input from wakefulness active neurons, local reflex mechanisms and central drive (e.g. pattern generator neurons to the largest upper airway muscle, genioglossus) [21]. The passive P_{crit} " technique used in the current study [14] was designed to reduce upper airway muscle activity by minimising local reflex input with continuous positive airway pressure. However, some individuals generate substantial reflex activation during these measurements [22, 23] and centrally controlled muscle activity remains, as evident by increases in passive P_{crit} during rapid eye movement (REM) sleep [22] and anaesthesia [24] when compared to non-REM sleep. Thus, while there is currently no evidence to indicate that insulin resistance alters the central mechanisms controlling the residual dilator muscle activity during the conditions used for passive P_{crit} measurement, the differences observed with insulin resistance in the current study may be, at least in part, due to impaired neuromuscular responses.

For example, obesity, primarily central obesity, is associated with increased circulating levels of inflammatory cytokines, some of which yield somnogenic central nervous system activity [25]. Obesity is also associated with blunted neuromuscular compensatory responses [25, 26]. It is conceivable that insulin resistance may augment these effects. Patients with untreated OSA are more prone to upper airway muscle fatigue [27, 28]. Insulin resistance is associated with lower leg muscle fatigue during a stair climbing task [29]. Thus, if insulin resistance also increases upper airway muscle fatigue, this could contribute to increased upper airway collapsibility.

An alternate mechanism by which insulin resistance might increase passive *P*_{crit} and the predisposition or progression of OSA is *via* damage to the soft tissues surrounding the pharynx. Diabetic neuropathy may




FIGURE 1 Schematic indicating the potential mechanisms by which insulin resistance might contribute to increased upper airway collapsibility and ultimately obstructive sleep apnoea (OSA). Some of the interconnections have been omitted for clarity. Refer to the text for further detail.

1612 DDI: 10.1183/13993003.00590-2016

impair the ability of the dilator muscles to protect pharyngeal patency [30]. However, diabetic neuropathy usually develops after prolonged diabetes mellitus, and typically first manifests as a sensory peripheral neuropathy. The role of systematic sensorimotor impairment in OSA pathogenesis is also unclear [27, 31]. Thus, while this mechanism cannot be discounted, the occurrence of a relevant asymptomatic insulin resistance-induced neuropathy confined to the upper airways, either sensory or motor, would appear unlikely. Similarly, while obesity and OSA are associated with structural alteration and inflammatory reactions in the extracellular matrix of upper airway tissue [32], the role of insulin resistance in these processes has not been evaluated.

In summary, while many uncertainties regarding the underlying mechanisms remain, the study in this issue of the European Respiratory Journal by LLANOS et al. [14] provides the first empiric evidence for a pathogenic contribution from insulin resistance to the primary cause of OSA, increased pharyngeal collapsibility. To extend the generalisability of this work beyond morbidly obese women (the average BMI of the participants was 48 kg·m⁻²), it will be important to determine if the reported relationships are also present in lean subjects, in men, and in longitudinal cohorts. Indeed, in light of recent findings [33, 34], morbidly obese individuals who do not have OSA likely have "supranormal" neuromuscular compensatory mechanisms that protect them from OSA. This concept is further supported by >50% of the study participants having a passive Pcrit above -2 cmH₂O and elevated AHIs during REM sleep into the pathogenic range when neuromuscular compensatory mechanisms are reduced or absent. However, given the differences in OSA pathophysiology between the sexes, it will be challenging to extend the current design to obese men with insulin resistance who do not have OSA as these individuals are rare. It will also be of interest to determine if other contributors to OSA pathophysiology that have been implicated with insulin resistance such as heightened peripheral chemosensitivity [35] cause respiratory control instability during sleep and have a causal role in OSA pathogenesis and/or disease progression. Finally, the intriguing possibility that insulin "sensitisers" may improve upper airway collapsibility in patients with OSA and insulin resistance warrants further investigation.

References

- Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 2015; 3: 310–318.
- 2 Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988–1992.
- 3 van der Aa MP, Fazeli Farsani S, Knibbe CA, et al. Population-based studies on the epidemiology of insulin resistance in children. J Diabetes Res 2015; 2015: 362375.
- 4 Bonsignore MR, Borel AL, Machan E, et al. Sleep apnoea and metabolic dysfunction. Eur Respir Rev 2013; 22: 353–364.
- 5 Poulain L, Thomas A, Rieusset J, *et al.* Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis. *Eur Respir J* 2014; 43: 513–522.
- 6 Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243–260.
- 7 Martinez Ceron E, Casitas Mateos R, Garcia-Rio F. Sleep apnea-hypopnea syndrome and type 2 diabetes. A reciprocal relationship? *Arch Bronconeumol* 2015; 51: 128–139.
- 8 Aurora RN, Punjabi NM. Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. Lancet Respir Med 2013; 1: 329–338.
- 9 Rajan P, Greenberg H. Obstructive sleep apnea as a risk factor for type 2 diabetes mellitus. *Nat Sci Sleep* 2015; 7: 113-125
- 10 Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 2003; 254: 32–44.
- 11 Koren D, Gozal D, Philby MF, et al. Impact of obstructive sleep apnoea on insulin resistance in nonobese and obese children. Eur Respir J 2016; 47: 1152–1161.
- Liu A, Ariel D, Lamendola C, et al. Comparison of the association with sleep apnoea of obesity versus insulin resistance. Eur Respir J 2015; 46: 1829–1832.
- Balkau B, Vol S, Loko S, et al. High baseline insulin levels associated with 6-year incident observed sleep apnea. Diabetes Care 2010; 33: 1044–1049.
- 14 Llanos OL, Galiatsatos P, Guzmán-Vélez E, et al. Pharyngeal collapsibility during sleep is elevated in insulin resistant females with morbid obesity. Eur Respir J 2016; 47: 1718–1726.
- 15 Polotsky VY, Li J, Punjabi NM, *et al.* Intermittent hypoxia increases insulin resistance in genetically obese mice. *J Physiol* 2003; 552: 253–264.
- Eckert DJ, Gandevia SC. The human upper airway: more than a floppy tube. *J Appl Physiol* 2014; 116: 288–290.
- 17 Van de Graaff WB. Thoracic influence on upper airway patency. J Appl Physiol 1988; 65: 2124–2131.
- 8 Kim AM, Keenan BT, Jackson N, et al. Tongue fat and its relationship to obstructive sleep apnea. Sleep 2014; 37: 1639–1648.
- 19 Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 2003; 168: 522–530.
- 20 Stadler DL, McEvoy RD, Sprecher KE, et al. Abdominal compression increases upper airway collapsibility during sleep in obese male obstructive sleep apnea patients. Sleep 2009; 32: 1579–1587.
- Jordan AS, White DP. Pharyngeal motor control and the pathogenesis of obstructive sleep apnea. Respir Physiol Neurobiol 2008; 160: 1–7.

- 22 Carberry JC, Jordan AS, White DP, et al. Upper Airway Collapsibility (Pcrit) and Pharyngeal Dilator Muscle Activity are Sleep-Stage Dependent. Sleep 2016; 39: 511–521.
- 23 Schwartz AR, O'Donnell CP, Baron J, et al. The hypotonic upper airway in obstructive sleep apnea: role of structures and neuromuscular activity. Am J Respir Crit Care Med 1998; 157: 1051–1057.
- 24 Oliven A, Aspandiarov E, Gankin I, et al. Collapsibility of the relaxed pharynx and risk of sleep apnoea. Eur Respir J 2008; 32: 1309–1315.
- 25 Schwartz AR, Patil SP, Squier S, et al. Obesity and upper airway control during sleep. J Appl Physiol 2010; 108: 430–435.
- 26 McGinley BM, Schwartz AR, Schneider H, et al. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. J Appl Physiol 2008; 105: 197–205.
- 27 Eckert DJ, Lo YL, Saboisky JP, et al. Sensorimotor function of the upper-airway muscles and respiratory sensory processing in untreated obstructive sleep apnea. J Appl Physiol 2011; 111: 1644–1653.
- 28 McSharry D, O'Connor C, McNicholas T, et al. Genioglossus fatigue in obstructive sleep apnea. Respir Physiol Neurobiol 2012; 183: 59-66.
- 29 Lafortuna CL, Prinelli F, Adorni F, et al. Effect of mechanical and metabolic factors on motor function and fatigue in obese men and women: a cross- sectional study. J Endocrinol Invest 2013; 36: 1062–1068.
- Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med 2012; 186: 434–441.
- 31 Saboisky JP, Butler JE, Gandevia SC, et al. Functional role of neural injury in obstructive sleep apnea. Front Neurol 2012; 3: 95.
- 32 Series F, Chakir J, Boivin D. Influence of weight and sleep apnea status on immunologic and structural features of the uvula. *Am J Respir Crit Care Med* 2004; 170: 1114–1119.
- 33 Cheng S, Brown EC, Hatt A, et al. Healthy humans with a narrow upper airway maintain patency during quiet breathing by dilating the airway during inspiration. J Physiol 2014; 592: 4763–4774.
- 34 Sands SA, Eckert DJ, Jordan AS, et al. Enhanced Upper-Airway Muscle Responsiveness Is a Distinct Feature of Overweight/Obese Individuals without Sleep Apnea. Am J Respir Crit Care Med 2014; 190: 930–937.
- 35 Ribeiro MJ, Sacramento JF, Gonzalez C, et al. Carotid body denervation prevents the development of insulin resistance and hypertension induced by hypercaloric diets. *Diabetes* 2013; 62: 2905–2916.

1614 DDI: 10.1183/13993003.00590-2016